Conditions: Choroidal Neovascularization Age-Related Maculopathy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 44
Healthy volunteers: no

Brief summary:
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.

Detailed description:

Arms:
arm 1: 700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.

Interventions: intervention 1: dexamethasone intervention 2: ranibizumab
Intervention descriptions: intervention 1: 700 µg dexamethasone intravitreal injection at Day 1 in the study eye. intervention 2: Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.

Protocol document: